{"id":"consolidation-therapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression"},{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Mucositis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Consolidation therapy is a post-remission treatment approach commonly used in acute leukemias and lymphomas after achieving initial remission with induction chemotherapy. It aims to eradicate minimal residual disease and prevent relapse by administering additional cycles of chemotherapy or targeted agents. The specific mechanism depends on the underlying drugs used in the consolidation regimen.","oneSentence":"Consolidation therapy refers to a treatment strategy that follows initial induction therapy to eliminate residual disease and improve long-term outcomes in hematologic malignancies.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:07:29.115Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute leukemia (post-induction consolidation)"},{"name":"Lymphoma (post-induction consolidation)"}]},"trialDetails":[{"nctId":"NCT02306161","phase":"PHASE3","title":"Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-12-12","conditions":"Metastatic Ewing Sarcoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Bone Marrow","enrollment":312},{"nctId":"NCT01167712","phase":"PHASE3","title":"Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2010-09-27","conditions":"Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma","enrollment":692},{"nctId":"NCT06514261","phase":"PHASE1","title":"Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-12-18","conditions":"Acute Myeloid Leukemia","enrollment":45},{"nctId":"NCT04310020","phase":"PHASE2","title":"Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-01-13","conditions":"Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8","enrollment":47},{"nctId":"NCT07055581","phase":"PHASE2","title":"Durvalumab as Consolidation for Patients LS-SCLC","status":"RECRUITING","sponsor":"Qian Chu","startDate":"2026-02-24","conditions":"Small Cell Lung Cancer Limited Stage","enrollment":100},{"nctId":"NCT00092222","phase":"PHASE2","title":"Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2004-10-28","conditions":"Lymphoproliferative Disorder, HHV-8, Malignancy","enrollment":75},{"nctId":"NCT00658814","phase":"PHASE2","title":"Azacitidine and Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2008-12-01","conditions":"Acute Myeloid Leukemia, Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia","enrollment":133},{"nctId":"NCT07495631","phase":"NA","title":"Pediatric-Inspired Regimen Combined With Venetoclax and Immunotherapy for Adult Ph-Negative Acute Lymphoblastic Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"Acute Lymphoblastic Leukemia, Adult","enrollment":80},{"nctId":"NCT06317649","phase":"PHASE2","title":"Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-09-27","conditions":"Acute Myeloid Leukemia","enrollment":147},{"nctId":"NCT05691478","phase":"PHASE2, PHASE3","title":"A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2023-03-03","conditions":"High Grade Osteosarcoma, Localized Osteosarcoma, Metastatic Osteosarcoma","enrollment":1122},{"nctId":"NCT06917911","phase":"PHASE2","title":"Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, \"7+3\") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MyeloMATCH Treatment Trial)","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-06-18","conditions":"Core Binding Factor Acute Myeloid Leukemia","enrollment":162},{"nctId":"NCT07498257","phase":"NA","title":"Adaptation and RCT of Written Exposure Therapy for Adolescents","status":"NOT_YET_RECRUITING","sponsor":"Medical University of South Carolina","startDate":"2026-03-05","conditions":"Posttraumatic Stress Disorder (PTSD)","enrollment":48},{"nctId":"NCT04503694","phase":"PHASE2","title":"Neoadjuvant Regorafenib in Combination With Nivolumab and Short-course Radiotherapy in Stage II-III Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jules Bordet Institute","startDate":"2021-03-25","conditions":"Rectal Cancer Stage II, Rectal Cancer Stage III","enrollment":72},{"nctId":"NCT06802523","phase":"PHASE1","title":"Testing the Combination of Targeted Radiotherapy With Anti-Cancer Drugs, Venetoclax and ASTX-727, to Improve Outcomes for Adults With Newly Diagnosed Acute Myeloid Leukemia","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2026-04-21","conditions":"Acute Myeloid Leukemia","enrollment":53},{"nctId":"NCT05564390","phase":"PHASE2","title":"MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-06-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":2000},{"nctId":"NCT04628026","phase":"PHASE3","title":"Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2","status":"RECRUITING","sponsor":"University of Ulm","startDate":"2022-09-13","conditions":"Acute Myeloid Leukemia","enrollment":650},{"nctId":"NCT04307576","phase":"PHASE3","title":"A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia","status":"RECRUITING","sponsor":"Mats Heyman","startDate":"2020-07-13","conditions":"Leukemia, Acute Lymphoblastic","enrollment":6430},{"nctId":"NCT01386385","phase":"PHASE1, PHASE2","title":"Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2011-06-20","conditions":"Lung Adenocarcinoma, Lung Adenocarcinoma, Mixed Subtype, Lung Large Cell Carcinoma","enrollment":53},{"nctId":"NCT04092283","phase":"PHASE3","title":"Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-04-29","conditions":"Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8","enrollment":660},{"nctId":"NCT04214262","phase":"PHASE3","title":"Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-08-13","conditions":"Lung Non-Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8","enrollment":480},{"nctId":"NCT05260528","phase":"PHASE2","title":"CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics","status":"RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nice","startDate":"2023-05-03","conditions":"Acute Myeloid Leukemia","enrollment":248},{"nctId":"NCT04402788","phase":"PHASE2, PHASE3","title":"Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-01-07","conditions":"Extensive Stage Lung Small Cell Carcinoma","enrollment":138},{"nctId":"NCT06992609","phase":"PHASE3","title":"Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-09-15","conditions":"Small Cell Lung Carcinoma","enrollment":70},{"nctId":"NCT07407140","phase":"PHASE3","title":"VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-04-30","conditions":"AML, Adult","enrollment":300},{"nctId":"NCT07493161","phase":"NA","title":"Chemotherapy With Targeted-Immunotherapy for Newly Diagnosed Ph+ ALL","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-04-01","conditions":"Ph+ ALL","enrollment":100},{"nctId":"NCT06313437","phase":"PHASE1","title":"Revumenib in Combination With 7+3 + Midostaurin in AML","status":"RECRUITING","sponsor":"Richard Stone, MD","startDate":"2024-12-06","conditions":"Acute Myeloid Leukemia, AML, Adult, AML With Gene Mutations","enrollment":22},{"nctId":"NCT04107727","phase":"PHASE2","title":"Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2019-09-05","conditions":"Acute Myeloid Leukemia","enrollment":273},{"nctId":"NCT06985498","phase":"PHASE2","title":"Immunotherapy Combined With Auto-HSCT and CD22/CD19 CAR-T Sandwich Strategy for B-ALL","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2026-06-01","conditions":"Acute Lymphobkastic Leukemia","enrollment":40},{"nctId":"NCT07490288","phase":"NA","title":"Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"AML","enrollment":30},{"nctId":"NCT07400029","phase":"PHASE2","title":"A Study of Obecabtagene Autoleucel in People With B-cell Acute Lymphoblastic Leukemia","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2026-02-03","conditions":"Acute Lymphoblastic Leukemia","enrollment":40},{"nctId":"NCT07489534","phase":"PHASE2","title":"Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal Dysfunction","status":"RECRUITING","sponsor":"Daihong Liu","startDate":"2025-09-29","conditions":"Multiple Myeloma","enrollment":25},{"nctId":"NCT06985485","phase":"PHASE2","title":"Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-05-17","conditions":"Acute Lymphoblastic Leukemia, Immunotherapy, Blinatumomab","enrollment":26},{"nctId":"NCT03391869","phase":"PHASE3","title":"Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-12-29","conditions":"Lung Adenocarcinoma, Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8","enrollment":339},{"nctId":"NCT07489066","phase":"PHASE2","title":"Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Pfizer","startDate":"2026-04-01","conditions":"Carcinoma, Non-Small-Cell Lung, Lung Cancer (NSCLC)","enrollment":120},{"nctId":"NCT02971397","phase":"PHASE1","title":"Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"Wake Forest University Health Sciences","startDate":"2016-11","conditions":"Acute Myeloid Leukemia","enrollment":40},{"nctId":"NCT06862622","phase":"","title":"Neural Representations of Memory Transformation (MEM_TRANS)","status":"NOT_YET_RECRUITING","sponsor":"Medical University of South Carolina","startDate":"2026-05-01","conditions":"Healthy Older Adults","enrollment":40},{"nctId":"NCT04680468","phase":"PHASE2","title":"Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2021-06-02","conditions":"Myeloma","enrollment":41},{"nctId":"NCT03267433","phase":"PHASE3","title":"Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2017-11-27","conditions":"Mantle Cell Lymphoma","enrollment":689},{"nctId":"NCT07486479","phase":"PHASE3","title":"Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2026-03-10","conditions":"Acute Myeloid Leukemia (AML)","enrollment":204},{"nctId":"NCT07485920","phase":"PHASE4","title":"A Prospective, Multicenter Exploratory Clinical Study on Consolidation Therapy With Tislelizumab Combined With Nintedanib for Limited-stage Small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"The Affiliated Hospital of Qingdao University","startDate":"2026-05-01","conditions":"Limited-stage Small Cell Lung Cancer (LS-SCLC)","enrollment":20},{"nctId":"NCT07485010","phase":"PHASE2","title":"Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial","status":"NOT_YET_RECRUITING","sponsor":"The University of Queensland","startDate":"2027-04","conditions":"Mycobacterium Abscessus Pulmonary Disease, Mycobacterium Abscessus Infection, Non-Tuberculous Mycobacterial (NTM) Infections","enrollment":300},{"nctId":"NCT07486726","phase":"PHASE1, PHASE2","title":"Aclarubicin Plus With Azacitidine and Venetoclax in the Treatment of Acute Myeloid Leukemia","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2026-03-15","conditions":"Acute Myeloid Leukemia (AML), Relapse Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia (AML)","enrollment":112},{"nctId":"NCT07486206","phase":"NA","title":"Optimizing the Follow-Up Journey in Interstitial Lung Disease: The OPTIMIZE-ILD-2 Trial","status":"RECRUITING","sponsor":"Hospital de Granollers","startDate":"2026-03-09","conditions":"Interstitial Lung Disease (ILD), Fibrotic Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis (IPF)","enrollment":152},{"nctId":"NCT05681260","phase":"PHASE3","title":"Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)","status":"RECRUITING","sponsor":"Children's Cancer Group, China","startDate":"2023-02-06","conditions":"T-cell Lymphoblastic Lymphoma","enrollment":200},{"nctId":"NCT06152809","phase":"PHASE1","title":"CIML NK Cells With Venetoclax for AML","status":"RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2024-02-20","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Recurrent, Leukemia","enrollment":10},{"nctId":"NCT06500273","phase":"PHASE2","title":"Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL","status":"RECRUITING","sponsor":"Allogene Therapeutics","startDate":"2024-06-18","conditions":"Large B-cell Lymphoma","enrollment":250},{"nctId":"NCT07478731","phase":"PHASE2","title":"Neoadjuvant SHR-1701 Plus Chemoradiotherapy for Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Hong Qiu","startDate":"2025-12-20","conditions":"CRC (Colorectal Cancer)","enrollment":48},{"nctId":"NCT03590171","phase":"PHASE2","title":"International Study for Treatment of High Risk Childhood Relapsed ALL 2010","status":"RECRUITING","sponsor":"Charite University, Berlin, Germany","startDate":"2017-09-01","conditions":"Acute Lymphoblastic Leukemia (ALL)","enrollment":250},{"nctId":"NCT05257083","phase":"PHASE3","title":"A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stichting European Myeloma Network","startDate":"2023-10-10","conditions":"Multiple Myeloma","enrollment":759},{"nctId":"NCT04133636","phase":"PHASE2","title":"A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2019-11-07","conditions":"Multiple Myeloma","enrollment":210},{"nctId":"NCT07021989","phase":"PHASE2","title":"ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Michael Spinner, MD","startDate":"2026-05-01","conditions":"Hodgkin Lymphoma, Adult, Refractory Hodgkin Lymphoma, Classic Hodgkin Lymphoma","enrollment":38},{"nctId":"NCT07476729","phase":"PHASE3","title":"International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)","status":"NOT_YET_RECRUITING","sponsor":"Charite University, Berlin, Germany","startDate":"2026-04-01","conditions":"B-Cell Acute Lymphoblastic Leukaemia","enrollment":750},{"nctId":"NCT02114229","phase":"PHASE2","title":"Phase 2 Study of Alisertib Therapy for Rhabdoid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2014-05-14","conditions":"Malignant Rhabdoid Tumor, Atypical Teratoid Rhabdoid Tumor","enrollment":125},{"nctId":"NCT06387615","phase":"NA","title":"Impact of Non-invasive Brain Stimulation on Learning Novel Spoken Words","status":"COMPLETED","sponsor":"Georgia State University","startDate":"2024-01-01","conditions":"Dyslexia, Dyslexia, Developmental, Learning; Developmental Disorder, Reading","enrollment":42},{"nctId":"NCT06561425","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Galapagos NV","startDate":"2022-03-09","conditions":"Relapsed/Refractory B-cell Non-Hodgkin Lymphoma, Lymphomas Non-Hodgkin&Amp;Amp;#39;s B-Cell","enrollment":130},{"nctId":"NCT06667908","phase":"PHASE2","title":"A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)","status":"RECRUITING","sponsor":"Johnson & Johnson Enterprise Innovation Inc.","startDate":"2024-12-06","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":130},{"nctId":"NCT05690984","phase":"PHASE2","title":"Elimination of Minimal Residual Disease After Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Medical College of Wisconsin","startDate":"2023-06-26","conditions":"Multiple Myeloma","enrollment":30},{"nctId":"NCT06138275","phase":"PHASE2","title":"Elranatamab in R/R Multiple Myeloma","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2024-03-08","conditions":"Refractory Multiple Myeloma, Relapse Multiple Myeloma, Multiple Myeloma","enrollment":32},{"nctId":"NCT03876769","phase":"PHASE2","title":"Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2019-06-24","conditions":"B-Cell Acute Lymphoblastic Leukemia","enrollment":121},{"nctId":"NCT06607458","phase":"PHASE2","title":"Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease","status":"RECRUITING","sponsor":"Delcath Systems Inc.","startDate":"2025-08-05","conditions":"Refractory Metastatic Colorectal Cancer","enrollment":90},{"nctId":"NCT00580515","phase":"NA","title":"Trial of Family Focused Grief Therapy in Palliative Care and Bereavement","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2005-11-08","conditions":"Cancer","enrollment":700},{"nctId":"NCT03591510","phase":"PHASE2","title":"A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2019-03-13","conditions":"FLT3-mutated Acute Myeloid Leukemia","enrollment":22},{"nctId":"NCT06577025","phase":"PHASE2","title":"A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-08-20","conditions":"Multiple Myeloma","enrollment":43},{"nctId":"NCT07007312","phase":"PHASE3","title":"Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML","status":"RECRUITING","sponsor":"Kura Oncology, Inc.","startDate":"2025-09-26","conditions":"Acute Myeloid Leukemia (AML)","enrollment":1300},{"nctId":"NCT06875128","phase":"PHASE2","title":"Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease","status":"RECRUITING","sponsor":"Delcath Systems Inc.","startDate":"2026-01-29","conditions":"Metastatic Breast Cancer in the Liver","enrollment":90},{"nctId":"NCT06550895","phase":"PHASE2","title":"A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2024-09-16","conditions":"Multiple Myeloma","enrollment":11},{"nctId":"NCT06854094","phase":"","title":"Consolidation Therapy With Cladribine in Relapsing Multiple Sclerosis Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ente Ospedaliero Cantonale, Bellinzona","startDate":"2024-10-03","conditions":"Multiple Sclerosis","enrollment":70},{"nctId":"NCT05602194","phase":"PHASE3","title":"Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma","status":"RECRUITING","sponsor":"Children's Oncology Group","startDate":"2023-08-14","conditions":"B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Acute Lymphoblastic Leukemia, BCR-ABL1-Like","enrollment":440},{"nctId":"NCT02213913","phase":"PHASE1, PHASE2","title":"Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas","status":"COMPLETED","sponsor":"University of Chicago","startDate":"2014-07-29","conditions":"Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Adult Diffuse Large Cell Lymphoma","enrollment":55},{"nctId":"NCT07464782","phase":"NA","title":"Self-care Psychoeducation Program for Trauma Counselors","status":"COMPLETED","sponsor":"TED University","startDate":"2023-12-01","conditions":"Self Care","enrollment":17},{"nctId":"NCT06193759","phase":"PHASE1","title":"Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT)","status":"RECRUITING","sponsor":"Children's National Research Institute","startDate":"2024-09-20","conditions":"Medulloblastoma, Childhood, Atypical Teratoid/Rhabdoid Tumor of CNS, Embryonal Tumor With Multilayered Rosettes","enrollment":12},{"nctId":"NCT07257419","phase":"PHASE1","title":"CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma","status":"RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2026-03-03","conditions":"Relapsed Pediatric ALL, Hematopoietic Cell Transplantation, Hematologic Malignancy","enrollment":60},{"nctId":"NCT02737046","phase":"PHASE2","title":"Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-Lymphoma","status":"COMPLETED","sponsor":"University of Miami","startDate":"2016-12-12","conditions":"Adult T-cell Leukemia-Lymphoma, ATLL","enrollment":15},{"nctId":"NCT03404193","phase":"PHASE2","title":"Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2018-01-18","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blastic Plasmacytoid Dendritic Cell Neoplasm","enrollment":235},{"nctId":"NCT03226418","phase":"PHASE2","title":"Geriatric Assessment & Genetic Profiling to Personalize Therapy in Older Adults With Acute Myeloid Leukemia","status":"COMPLETED","sponsor":"University of Nebraska","startDate":"2017-07-07","conditions":"Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia","enrollment":75},{"nctId":"NCT04431011","phase":"","title":"Layer-specific Contribution to Consolidation of Skill Learning in the Primary Motor Cortex","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2021-04-21","conditions":"Normal Physiology","enrollment":40},{"nctId":"NCT03477539","phase":"PHASE2","title":"Daratumumab in Treating Transplant-Eligible Patients With Multiple Myeloma","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2018-04-09","conditions":"Plasma Cell Myeloma","enrollment":49},{"nctId":"NCT04231851","phase":"PHASE2","title":"CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-related Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, Irvine","startDate":"2020-02-19","conditions":"Acute Myelogenous Leukemia (AML) Due to Therapy, Acute Myeloid Leukemia With Myelodysplasia-Related Changes","enrollment":30},{"nctId":"NCT07060001","phase":"PHASE2","title":"Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker","status":"NOT_YET_RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2026-04","conditions":"Acute Myeloid Leukemia (AML), Acute Myeloid Leukaemia (AML)","enrollment":112},{"nctId":"NCT02835222","phase":"PHASE2","title":"Selinexor With Combination With Induction/Consolidation Therapy in Acute Myeloid Leukemia Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2018-02-02","conditions":"Untreated Adult Acute Myeloid Leukemia","enrollment":57},{"nctId":"NCT05502250","phase":"PHASE2","title":"Tislelizumab, Gemcitabine and Cisplatin for R/R Hodgkin Lymphoma Followed by Tislelizumab Consolidation in Patients in Metabolic Complete Remission","status":"ACTIVE_NOT_RECRUITING","sponsor":"Stichting Hemato-Oncologie voor Volwassenen Nederland","startDate":"2023-07-14","conditions":"Hodgkin Lymphoma","enrollment":75},{"nctId":"NCT05306301","phase":"PHASE2","title":"Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2022-10-05","conditions":"Chemotherapy, Leukemia, Acute Lymphoblastic","enrollment":32},{"nctId":"NCT07454226","phase":"NA","title":"ABL/JAK Inhibitors With Chemotherapy and Venetoclax for Ph-like ALL","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-01","conditions":"Ph-Like, Acute Lymphoblastic Leukemia","enrollment":30},{"nctId":"NCT03652441","phase":"PHASE2","title":"Consolidation Therapy With Brentuximab Vedotin After Allogeneic Stem Cell Transplantation for Relapsed or Refractory Hodgkin Lymphoma","status":"COMPLETED","sponsor":"University of Cologne","startDate":"2019-11-13","conditions":"Classical Hodgkin Lymphoma","enrollment":14},{"nctId":"NCT03214562","phase":"PHASE1, PHASE2","title":"Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-09-26","conditions":"High Risk Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia","enrollment":116},{"nctId":"NCT06253637","phase":"PHASE2","title":"Daratumumab in VHR T-ALL Treated According to the ALL National Treatment Program","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gruppo Italiano Malattie EMatologiche dell'Adulto","startDate":"2024-10-17","conditions":"T-Lymphocytic Leukemia, Acute","enrollment":31},{"nctId":"NCT07010263","phase":"PHASE3","title":"A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy","status":"RECRUITING","sponsor":"Akeso","startDate":"2025-06-13","conditions":"Small Cell Lung Cancer","enrollment":560},{"nctId":"NCT01805609","phase":"NA","title":"Training Model to Advance Support of the Family as a Caregiving System in the Inpatient Oncology Setting","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2013-02","conditions":"Support of the Family as a Caregiving System","enrollment":80},{"nctId":"NCT07451912","phase":"PHASE1, PHASE2","title":"Venetoclax Plus Hypomethylating Agents and Subcutaneous Cytarabine for CEBPA-Mutated AML","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2025-09-15","conditions":"Acute Myeloid Leukemia (AML), CEBPA Mutation, Unfit, New-diagnosis AML","enrollment":29},{"nctId":"NCT04802356","phase":"PHASE2","title":"Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"PETHEMA Foundation","startDate":"2021-04-07","conditions":"Multiple Myeloma","enrollment":50},{"nctId":"NCT05933109","phase":"NA","title":"Mental Imagery and Targeted Memory Reactivation in PTSD","status":"COMPLETED","sponsor":"University Hospital, Geneva","startDate":"2023-03-01","conditions":"Nightmares, REM-Sleep Type, PTSD","enrollment":46},{"nctId":"NCT06066346","phase":"PHASE2","title":"A Study of Talquetamab for People With Multiple Myeloma Who Have Received BCMA CAR T-Cell Therapy","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2023-09-27","conditions":"Multiple Myeloma","enrollment":17},{"nctId":"NCT04716946","phase":"PHASE2","title":"Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2021-01-27","conditions":"NSCLC, Non-small Cell Lung Cancer, Lung Cancer","enrollment":13},{"nctId":"NCT07223190","phase":"PHASE3","title":"A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Lymphoblastic Leukaemia","status":"NOT_YET_RECRUITING","sponsor":"Amgen","startDate":"2026-06-11","conditions":"Philadelphia Chromosome Negative B-cell Precursor Acute Lymphoblastic Leukemia","enrollment":560},{"nctId":"NCT06335784","phase":"NA","title":"Mental Imagery and Targeted Memory Reactivation in Insomnia","status":"RECRUITING","sponsor":"University Hospital, Geneva","startDate":"2024-04-22","conditions":"Insomnia Disorder","enrollment":120},{"nctId":"NCT06719700","phase":"PHASE2","title":"Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-11-30","conditions":"Toripalimab, Surufatinib, Chemoradiotherapy","enrollment":47},{"nctId":"NCT06481241","phase":"NA","title":"Efficacy and Safety of Chemotherapy Combined With CAR-T Cells in Newly Diagnosed Adult Patients With Ph- B-ALL","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2024-06-10","conditions":"Philadelphia Chromosome Negative ALL, Acute Lymphoblastic Leukemia, Adult","enrollment":77},{"nctId":"NCT07443488","phase":"PHASE2","title":"Efficacy and Safety of Olverembatinib Plus Inotuzumab Ozogamicin as First-Line Consolidation Therapy Followed by HSCT in Ph+ ALL","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2026-03-14","conditions":"HSCT, Ph+ ALL","enrollment":20},{"nctId":"NCT07444060","phase":"","title":"Guselkumab Vs Ustekinumab in Stricturing Crohn's Disease","status":"RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2026-03-01","conditions":"CD - Crohn's Disease, Stricture; Bowel, IBD - Inflammatory Bowel Disease","enrollment":100},{"nctId":"NCT07132684","phase":"PHASE3","title":"Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients","status":"RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-08-31","conditions":"AML, Adult","enrollment":240}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2360,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Consolidation","intensification therapy","Post Remission Therapy","Postremission Therapy"],"phase":"phase_3","status":"active","brandName":"Consolidation Therapy","genericName":"Consolidation Therapy","companyName":"Institute of Hematology & Blood Diseases Hospital, China","companyId":"institute-of-hematology-blood-diseases-hospital-china","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Consolidation Therapy is a treatment approach that has been studied in various clinical trials for conditions such as Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and High-risk Myelodysplastic Syndrome. The therapy involves interventions like ITMHA, Dexamethasone, and Mitoxantrone, and its mechanism is related to gene therapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}